ReviewJournal of clinical medicine2026
Left Ventricular Ejection Fraction in Heart Failure-A Parameter to Be Discontinued?
Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is a multifactorial and heterogeneous syndrome with substantial epidemiological burden, high mortality, and impact on quality of life. In the context of heart failure, left ventricular ejection fraction (LVEF) has been regarded as the most important marker of systolic function and is fundamental in medical research and clinical practice. In research, LVEF has been a major inclusion criterion in most clinical trials over the past few decades. Furthermore, international heart failure guidelines rely on LVEF for the diagnosis of HF and to guide effective treatment. Additionally, our understanding of HF phenotypes and prognosis is mostly grounded in a classification based on LVEF. Nevertheless, there has been a growing debate regarding the role of LVEF in heart failure. In this context, the purpose of this review is to discuss both the advantages and contemporary relevance of LVEF in heart failure, as well as its limitations and controversies. In addition, this review aims to discuss potential alternatives and future directions in heart failure classification, such as new classification methods, alternative measurements of systolic function and imaging techniques, the HLM score, and the use of artificial intelligence and machine learning.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.